A multicenter, cooperative, randomized, comparative study regarding the efficacy of denosumab for bone loss related to postoperative endocrine therapy in postmenopausal patients with hormone-sensitive breast cancer
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Denosumab (Primary) ; Aromatase inhibitors
- Indications Early breast cancer; Osteoporosis
- Focus Therapeutic Use
- 16 May 2017 Status changed from not yet recruiting to recruiting.
- 23 Nov 2016 Planned initiation date changed from 1 Aug 2016 to 15 Dec 2016.
- 11 Jul 2016 New trial record